and prevention of UGI bleeding from severe gastricacid-related disorders [1–4]. High-dose parenteral
PPIs have also recently been introduced to provide
rapid acid suppression when the patient’s medical
condition precludes giving oral formulations [1].
When added to standard endoscopic treatment,
the intravenous (iv) formulation of PPIs is more effi-
cacious than placebo to prevent bleeding recurrences from peptic ulcers [5–7]. However, the
randomized trials showing a beneficial effect of iv
PPIs were performed on persons with endoscopically confirmed lesions. In actual practice, a con-
firmatory endoscopy is often delayed up to 24 hours
and sometimes even longer [8–10]. Initiating iv PPI